Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies

We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including intravenous cyclophosphamide. Nintedanib has just b...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanagihara, Toyoshi, Suzuki, Kunihiro, Egashira, Ayaka, Ogo, Naruhiko, Asoh, Tatsuma, Nara, Tsukasa, Takatsuki, Kensaku, Yoshizawa, Seiji, Chong, Sy Giin, Hamada, Naoki, Maeyama, Takashige
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606860/
https://www.ncbi.nlm.nih.gov/pubmed/33163354
http://dx.doi.org/10.1016/j.rmcr.2020.101272
Descripción
Sumario:We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including intravenous cyclophosphamide. Nintedanib has just been approved for treatment of progressive fibrosing ILD, but to date, no reports of RP-ILD treated with nintedanib have been published. This case report may advance discussions regarding the use and timing of nintedanib in treating RP-ILD.

Ejemplares similares